Review



retroviral plasmids pretrosuper puro shsmad2  (Addgene inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Addgene inc retroviral plasmids pretrosuper puro shsmad2
    a, Western analysis of SMAD2, SMAD3, and ACTIN (loading control) levels in SKD-HMEC expressing shRNAs targeting GFP (shGFP), SMAD2 <t>(shSMAD2),</t> or SMAD3 (shSMAD3). b-f, SKD-HMEC expressing shRNAs targeting GFP (shGFP), SMAD2 (shSMAD2), or SMAD3 (shSMAD3) were left untreated or treated with recombinant OSM [10 ng/mL] for 10 days and then subjected to the following assays. b, Relative growth assays of shGFP-, shSMAD2-, and shSMAD3-expressing HMEC grown in the presence (+) and absence (−) of OSM. Mean ± SEM (error bars) of all triplicates are presented for each sample. c, Senescence-associated β-galactosidase (SA-β-Gal) activity staining (blue) in untreated shGFP-, shSMAD2-, and shSMAD3-expressing HMEC and cells treated with OSM. Scale bar, 150 μm. d, Flow cytometry of CD24 and CD44 surface-profile expression in shGFP-, shSMAD2-, and shSMAD3-expressing SKD-HMEC grown in the presence (+) and absence (−) of OSM. CD44LO cells are shown as red and CD44HI cells as blue. Black numbers represent the percent of total cell population that are CD44HI. e, qRT-PCR analysis of cells grown in the presence (+) and absence (−) of OSM using primers targeting CD44s (SC gene; left) and SNAI1 (EMT gene; right) f, Following treatment with OSM [10 ng/mL] for 10 days, mRNA was harvested from shGFP-, shSMAD2-, or shSMAD3-expressing SKD-HMEC and subjected to a targeted Human EMT qRT-PCR profiler array. Heat map displaying non-supervised hierarchical clustering of fold-regulation gene expression data between OSM-treated cells relative to untreated shGFP-cells with the brightest green representing the smallest value, brightest red the highest value, and black the average magnitude of gene expression. Error bars indicate mean ± SEM of three independent experiments. Statistically significant differences are indicated with * when P < 0.05, ** when P < 0.01, *** when P < 0.001, and **** when P < 0.0001. Differences with a P value > 0.05 were considered non-significant and indicated with ns.
    Retroviral Plasmids Pretrosuper Puro Shsmad2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/retroviral plasmids pretrosuper puro shsmad2/product/Addgene inc
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    retroviral plasmids pretrosuper puro shsmad2 - by Bioz Stars, 2024-10
    93/100 stars

    Images

    1) Product Images from "Aberrant induction of a mesenchymal/stem-cell program engages senescence in normal mammary epithelial cells."

    Article Title: Aberrant induction of a mesenchymal/stem-cell program engages senescence in normal mammary epithelial cells.

    Journal: Molecular cancer research : MCR

    doi: 10.1158/1541-7786.MCR-19-1181

    a, Western analysis of SMAD2, SMAD3, and ACTIN (loading control) levels in SKD-HMEC expressing shRNAs targeting GFP (shGFP), SMAD2 (shSMAD2), or SMAD3 (shSMAD3). b-f, SKD-HMEC expressing shRNAs targeting GFP (shGFP), SMAD2 (shSMAD2), or SMAD3 (shSMAD3) were left untreated or treated with recombinant OSM [10 ng/mL] for 10 days and then subjected to the following assays. b, Relative growth assays of shGFP-, shSMAD2-, and shSMAD3-expressing HMEC grown in the presence (+) and absence (−) of OSM. Mean ± SEM (error bars) of all triplicates are presented for each sample. c, Senescence-associated β-galactosidase (SA-β-Gal) activity staining (blue) in untreated shGFP-, shSMAD2-, and shSMAD3-expressing HMEC and cells treated with OSM. Scale bar, 150 μm. d, Flow cytometry of CD24 and CD44 surface-profile expression in shGFP-, shSMAD2-, and shSMAD3-expressing SKD-HMEC grown in the presence (+) and absence (−) of OSM. CD44LO cells are shown as red and CD44HI cells as blue. Black numbers represent the percent of total cell population that are CD44HI. e, qRT-PCR analysis of cells grown in the presence (+) and absence (−) of OSM using primers targeting CD44s (SC gene; left) and SNAI1 (EMT gene; right) f, Following treatment with OSM [10 ng/mL] for 10 days, mRNA was harvested from shGFP-, shSMAD2-, or shSMAD3-expressing SKD-HMEC and subjected to a targeted Human EMT qRT-PCR profiler array. Heat map displaying non-supervised hierarchical clustering of fold-regulation gene expression data between OSM-treated cells relative to untreated shGFP-cells with the brightest green representing the smallest value, brightest red the highest value, and black the average magnitude of gene expression. Error bars indicate mean ± SEM of three independent experiments. Statistically significant differences are indicated with * when P < 0.05, ** when P < 0.01, *** when P < 0.001, and **** when P < 0.0001. Differences with a P value > 0.05 were considered non-significant and indicated with ns.
    Figure Legend Snippet: a, Western analysis of SMAD2, SMAD3, and ACTIN (loading control) levels in SKD-HMEC expressing shRNAs targeting GFP (shGFP), SMAD2 (shSMAD2), or SMAD3 (shSMAD3). b-f, SKD-HMEC expressing shRNAs targeting GFP (shGFP), SMAD2 (shSMAD2), or SMAD3 (shSMAD3) were left untreated or treated with recombinant OSM [10 ng/mL] for 10 days and then subjected to the following assays. b, Relative growth assays of shGFP-, shSMAD2-, and shSMAD3-expressing HMEC grown in the presence (+) and absence (−) of OSM. Mean ± SEM (error bars) of all triplicates are presented for each sample. c, Senescence-associated β-galactosidase (SA-β-Gal) activity staining (blue) in untreated shGFP-, shSMAD2-, and shSMAD3-expressing HMEC and cells treated with OSM. Scale bar, 150 μm. d, Flow cytometry of CD24 and CD44 surface-profile expression in shGFP-, shSMAD2-, and shSMAD3-expressing SKD-HMEC grown in the presence (+) and absence (−) of OSM. CD44LO cells are shown as red and CD44HI cells as blue. Black numbers represent the percent of total cell population that are CD44HI. e, qRT-PCR analysis of cells grown in the presence (+) and absence (−) of OSM using primers targeting CD44s (SC gene; left) and SNAI1 (EMT gene; right) f, Following treatment with OSM [10 ng/mL] for 10 days, mRNA was harvested from shGFP-, shSMAD2-, or shSMAD3-expressing SKD-HMEC and subjected to a targeted Human EMT qRT-PCR profiler array. Heat map displaying non-supervised hierarchical clustering of fold-regulation gene expression data between OSM-treated cells relative to untreated shGFP-cells with the brightest green representing the smallest value, brightest red the highest value, and black the average magnitude of gene expression. Error bars indicate mean ± SEM of three independent experiments. Statistically significant differences are indicated with * when P < 0.05, ** when P < 0.01, *** when P < 0.001, and **** when P < 0.0001. Differences with a P value > 0.05 were considered non-significant and indicated with ns.

    Techniques Used: Western Blot, Expressing, Recombinant, Activity Assay, Staining, Flow Cytometry, Quantitative RT-PCR



    Similar Products

    retroviral plasmids pretrosuper puro shsmad2  (Addgene inc)
    93
    Addgene inc retroviral plasmids pretrosuper puro shsmad2
    a, Western analysis of SMAD2, SMAD3, and ACTIN (loading control) levels in SKD-HMEC expressing shRNAs targeting GFP (shGFP), SMAD2 <t>(shSMAD2),</t> or SMAD3 (shSMAD3). b-f, SKD-HMEC expressing shRNAs targeting GFP (shGFP), SMAD2 (shSMAD2), or SMAD3 (shSMAD3) were left untreated or treated with recombinant OSM [10 ng/mL] for 10 days and then subjected to the following assays. b, Relative growth assays of shGFP-, shSMAD2-, and shSMAD3-expressing HMEC grown in the presence (+) and absence (−) of OSM. Mean ± SEM (error bars) of all triplicates are presented for each sample. c, Senescence-associated β-galactosidase (SA-β-Gal) activity staining (blue) in untreated shGFP-, shSMAD2-, and shSMAD3-expressing HMEC and cells treated with OSM. Scale bar, 150 μm. d, Flow cytometry of CD24 and CD44 surface-profile expression in shGFP-, shSMAD2-, and shSMAD3-expressing SKD-HMEC grown in the presence (+) and absence (−) of OSM. CD44LO cells are shown as red and CD44HI cells as blue. Black numbers represent the percent of total cell population that are CD44HI. e, qRT-PCR analysis of cells grown in the presence (+) and absence (−) of OSM using primers targeting CD44s (SC gene; left) and SNAI1 (EMT gene; right) f, Following treatment with OSM [10 ng/mL] for 10 days, mRNA was harvested from shGFP-, shSMAD2-, or shSMAD3-expressing SKD-HMEC and subjected to a targeted Human EMT qRT-PCR profiler array. Heat map displaying non-supervised hierarchical clustering of fold-regulation gene expression data between OSM-treated cells relative to untreated shGFP-cells with the brightest green representing the smallest value, brightest red the highest value, and black the average magnitude of gene expression. Error bars indicate mean ± SEM of three independent experiments. Statistically significant differences are indicated with * when P < 0.05, ** when P < 0.01, *** when P < 0.001, and **** when P < 0.0001. Differences with a P value > 0.05 were considered non-significant and indicated with ns.
    Retroviral Plasmids Pretrosuper Puro Shsmad2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/retroviral plasmids pretrosuper puro shsmad2/product/Addgene inc
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    retroviral plasmids pretrosuper puro shsmad2 - by Bioz Stars, 2024-10
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    a, Western analysis of SMAD2, SMAD3, and ACTIN (loading control) levels in SKD-HMEC expressing shRNAs targeting GFP (shGFP), SMAD2 (shSMAD2), or SMAD3 (shSMAD3). b-f, SKD-HMEC expressing shRNAs targeting GFP (shGFP), SMAD2 (shSMAD2), or SMAD3 (shSMAD3) were left untreated or treated with recombinant OSM [10 ng/mL] for 10 days and then subjected to the following assays. b, Relative growth assays of shGFP-, shSMAD2-, and shSMAD3-expressing HMEC grown in the presence (+) and absence (−) of OSM. Mean ± SEM (error bars) of all triplicates are presented for each sample. c, Senescence-associated β-galactosidase (SA-β-Gal) activity staining (blue) in untreated shGFP-, shSMAD2-, and shSMAD3-expressing HMEC and cells treated with OSM. Scale bar, 150 μm. d, Flow cytometry of CD24 and CD44 surface-profile expression in shGFP-, shSMAD2-, and shSMAD3-expressing SKD-HMEC grown in the presence (+) and absence (−) of OSM. CD44LO cells are shown as red and CD44HI cells as blue. Black numbers represent the percent of total cell population that are CD44HI. e, qRT-PCR analysis of cells grown in the presence (+) and absence (−) of OSM using primers targeting CD44s (SC gene; left) and SNAI1 (EMT gene; right) f, Following treatment with OSM [10 ng/mL] for 10 days, mRNA was harvested from shGFP-, shSMAD2-, or shSMAD3-expressing SKD-HMEC and subjected to a targeted Human EMT qRT-PCR profiler array. Heat map displaying non-supervised hierarchical clustering of fold-regulation gene expression data between OSM-treated cells relative to untreated shGFP-cells with the brightest green representing the smallest value, brightest red the highest value, and black the average magnitude of gene expression. Error bars indicate mean ± SEM of three independent experiments. Statistically significant differences are indicated with * when P < 0.05, ** when P < 0.01, *** when P < 0.001, and **** when P < 0.0001. Differences with a P value > 0.05 were considered non-significant and indicated with ns.

    Journal: Molecular cancer research : MCR

    Article Title: Aberrant induction of a mesenchymal/stem-cell program engages senescence in normal mammary epithelial cells.

    doi: 10.1158/1541-7786.MCR-19-1181

    Figure Lengend Snippet: a, Western analysis of SMAD2, SMAD3, and ACTIN (loading control) levels in SKD-HMEC expressing shRNAs targeting GFP (shGFP), SMAD2 (shSMAD2), or SMAD3 (shSMAD3). b-f, SKD-HMEC expressing shRNAs targeting GFP (shGFP), SMAD2 (shSMAD2), or SMAD3 (shSMAD3) were left untreated or treated with recombinant OSM [10 ng/mL] for 10 days and then subjected to the following assays. b, Relative growth assays of shGFP-, shSMAD2-, and shSMAD3-expressing HMEC grown in the presence (+) and absence (−) of OSM. Mean ± SEM (error bars) of all triplicates are presented for each sample. c, Senescence-associated β-galactosidase (SA-β-Gal) activity staining (blue) in untreated shGFP-, shSMAD2-, and shSMAD3-expressing HMEC and cells treated with OSM. Scale bar, 150 μm. d, Flow cytometry of CD24 and CD44 surface-profile expression in shGFP-, shSMAD2-, and shSMAD3-expressing SKD-HMEC grown in the presence (+) and absence (−) of OSM. CD44LO cells are shown as red and CD44HI cells as blue. Black numbers represent the percent of total cell population that are CD44HI. e, qRT-PCR analysis of cells grown in the presence (+) and absence (−) of OSM using primers targeting CD44s (SC gene; left) and SNAI1 (EMT gene; right) f, Following treatment with OSM [10 ng/mL] for 10 days, mRNA was harvested from shGFP-, shSMAD2-, or shSMAD3-expressing SKD-HMEC and subjected to a targeted Human EMT qRT-PCR profiler array. Heat map displaying non-supervised hierarchical clustering of fold-regulation gene expression data between OSM-treated cells relative to untreated shGFP-cells with the brightest green representing the smallest value, brightest red the highest value, and black the average magnitude of gene expression. Error bars indicate mean ± SEM of three independent experiments. Statistically significant differences are indicated with * when P < 0.05, ** when P < 0.01, *** when P < 0.001, and **** when P < 0.0001. Differences with a P value > 0.05 were considered non-significant and indicated with ns.

    Article Snippet: 15 , 16 , 20 The retroviral plasmids pRetroSUPER-Puro shSMAD2 and pRetroSUPER-Puro shSMAD3 (Addgene plasmid #s 15722 and 15726) were gifts from and deposited to Addgene by Dr. Joan Massague (Memorial Sloan-Kettering Cancer Center); and pRetroSUPER-Puro shGFP was obtained from Dr. Yosef Shiloh (Department of Neurobiology, Tel Aviv University, Tel Aviv, Israel).

    Techniques: Western Blot, Expressing, Recombinant, Activity Assay, Staining, Flow Cytometry, Quantitative RT-PCR